文献速递妇科肿瘤

高级别浆液性卵巢癌单细胞空间图谱揭示MHC II类分子为空间肿瘤生态与临床结局的关键预测因子

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.
PubMed 文献 · Cancer Discov · 2026-01-01

本研究构建了280例转移性高级别浆液性卵巢癌(HGSC)的单细胞空间图谱,整合高维成像与分子图谱分析929个单细胞图谱。研究发现肿瘤-间质界面免疫细胞共浸润影响临床结局,肿瘤细胞MHC II类分子(MHCII)表达是延长生存的关键预测因子,并验证其与免疫激活、抗原提呈及PD-1阻断后CD8+ T细胞毒性相关。

要点

  • 肿瘤细胞MHCII表达是HGSC延长生存的关键预测因子。
  • 肿瘤-间质界面免疫细胞共浸润影响HGSC临床结局。
  • 肿瘤MHCII表达与PD-1阻断后CD8+ T细胞毒性增加相关。

核心结论

  • 肿瘤内在MHCII是局部免疫激活和免疫治疗反应性的关键驱动因子,可作为改善HGSC患者分层和治疗决策的机制性生物标志物。

研究设计与样本

  • 研究构建了来自280例转移性HGSC患者的单细胞空间图谱,整合高维成像和分子图谱,分析929个单细胞图谱。

主要发现

  • 识别出具有多样细胞组成的空间域,肿瘤-间质界面免疫细胞共浸润影响临床结局。
  • 利用CEFIIRA方法发现肿瘤细胞MHCII表达是延长生存的关键预测因子。
  • 去卷积单细胞和两个独立空间转录组数据集及免疫肽组学分析证实MHCII表达与免疫激活、抗原提呈和T细胞受体克隆性相关。
  • 患者来源免疫肿瘤学平台显示肿瘤MHCII表达与PD-1阻断后CD8+ T细胞毒性增加相关,而阻断MHCII抑制该激活。

临床怎么用

  • 肿瘤MHCII表达可作为HGSC患者分层和免疫治疗决策的机制性生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant-host cell interactions, yet its orchestration remains poorly understood. We present a single-cell spatial atlas of metastatic HGSC from 280 patients, integrating high-dimensional imaging and molecular profiling. Analyzing 929 single-cell maps, we identify spatial domains with diverse cell compositions and show that immune cell coinfiltration at the tumor-stroma interface affects clinical outcomes. Using Cell Feature Importance Identification by RAndom forest (CEFIIRA), we find that tumor cell MHC class II (MHCII) expression is a key predictor of prolonged survival. Validation with deconvoluted single-cell and two distinct spatial transcriptomic datasets, along with immunopeptidomic analysis, confirms that MHCII expression correlates with immune activation, antigen presentation, and T-cell receptor clonality. Using a patient-derived immuno-oncology platform, we demonstrate that tumor MHCII expression associates with increased CD8+ T-cell cytotoxicity after PD-1 blockade, whereas blocking MHCII inhibits this activation. Our atlas offers new insights into immune activation, potentially improving patient stratification in HGSC. SIGNIFICANCE: This study delivers the first large-scale single-cell spatial atlas of HGSC, revealing how tumor-immune organization shapes outcomes. We identify tumor-intrinsic MHCII as a key driver of local immune activation and immunotherapy responsiveness, providing a mechanistic biomarker that can immediately inform improved patient stratification and therapeutic decision-making in ovarian cancer. See related commentary by Conejo-Garcia and Dangaj Laniti, p. 1041.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Perez-Villatoro F, Shabanova A, van Wagensveld L, et al. Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes. Cancer Discov. 2026. PMID: 41661089. doi:10.1158/2159-8290.CD-25-1492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。